Abstract
In this issue of the Journal, Gennari et al. ( 1 ) report results of a meta-analysis of eight published studies that tested the worth of HER2 as a predictive marker of benefit from anthracycline regimens over nonanthracycline regimens. The test for treatment by HER2 status interaction yielded statistically significant results. The authors propose that it is time to stop the use of cardiotoxic anthracycline regimens for the treatment of HER2 -negative breast cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
